Moderna, Inc. (MRNA) Advances Flu, RSV, and Cancer mRNA Therapies Beyond COVID

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Moderna, Inc. is placed among them.

Moderna, Inc. (NASDAQ:MRNA), a Cambridge-based biotechnology leader, specializes in mRNA therapeutics and vaccines, including its flagship COVID-19 vaccine. Beyond the pandemic, the company is expanding its pipeline with vaccines for influenza, RSV, CMV, Zika, and combination vaccines targeting multiple respiratory pathogens, alongside mRNA therapeutics for oncology, rare diseases, and cardiovascular conditions. MRNA operates globally with manufacturing in the U.S. and Europe, leveraging strategic alliances and technology transfers to scale its operations.

In September 2025, Moderna, Inc. (NASDAQ:MRNA) faced market headwinds as its stock fell nearly 7%, triggered by reports linking COVID-19 vaccines to about 25 child deaths, a claim lacking scientific consensus but fueling investor concerns and regulatory scrutiny. Policy shifts, including Florida’s removal of vaccine mandates, further cloud near-term demand forecasts.

Despite these challenges, the firm emphasizes transparency and scientific rigor, citing extensive real-world data with over a billion doses administered worldwide. This ongoing focus on safety underpins public trust and regulatory engagement.

Moderna, Inc. (MRNA) Advances Flu, RSV, and Cancer mRNA Therapies Beyond COVID

Innovation remains central to Moderna, Inc. (NASDAQ:MRNA)’s strategy, with the company broadening mRNA applications beyond COVID-19. AI and machine learning are increasingly integrated into MRNA’s R&D pipeline to accelerate mRNA design, optimize vaccine formulations, and predict immune responses. This combination of scientific rigor and technological edge reinforces MRNA’s standing among the best biotech stocks adapting to future healthcare needs.

While we acknowledge the risk and potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRNA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.